Skip to main content

Table 3 Mean change in YMRS, MADRS, BAI and SF-12 at one year by single SGA received

From: A Canadian naturalistic study of a community-based cohort treated for bipolar disorder

Single SGA
Received
LS Mean for
Change from
Baseline to
One Year with Propensity Adjustment
95% Confidence Interval Pvalue*
YMRS    
olanzapine (n = 154) -15.9 -16.7 to -15.2 0.835
risperidone (n = 41) -15.9 -17.3 to -14.5  
quetiapine (n = 38) -15.5 -16.9 to -14.1  
MADRS    
olanzapine (n = 154) -7.5 -8.8 to -6.2 0.552
risperidone (n = 42) -6.2 -8.7 to -3.7  
quetiapine (n = 37) -7.8 -10.4 to -5.3  
BAI    
olanzapine (n = 132) -7.0 -8.4 to -5.6 0.935
risperidone (n = 34) -6.9 -9.7 to -4.1  
quetiapine (n = 32) -6.4 -9.4 to -3.5  
SF-12 Mental Composite    
olanzapine (n = 127) 6.3 4.0 to 8.7  
risperidone (n = 37) 5.0 0.5 to 9.5 0.057
quetiapine (n = 31) 11.9 7.1 to 16.8  
SF-12 Physical Composite    
olanzapine (n = 127) 0.6 -1.4 to 2.5 0.077
risperidone (n = 37) -0.7 -4.4 to 3.0  
quetiapine (n = 31) -4.4 -8.4 to -0.5  
  1. SGA: second generation antipsychotic
  2. YMRS: Young Mania Rating Scale
  3. MADRS: Montgomery Asberg Depression Rating Scale
  4. BAI: Beck Anxiety Inventory
  5. *P value from F-test for any differences among the effects of the three single SGAs